SB-913
SB-913-1602
Phase 2 mab terminated
Quick answer
SB-913 for Mucopolysaccharidosis II is a Phase 2 program (mab) at SANGAMO THERAPEUTICS, INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- SANGAMO THERAPEUTICS, INC
- Indication
- Mucopolysaccharidosis II
- Phase
- Phase 2
- Modality
- mab
- Status
- terminated